查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850406

核子醫學影像設備市場（按產品、放射性藥物、應用和最終用戶分類）—2025-2032年全球預測

Nuclear Imaging Equipment Market by Product, Radiopharmaceuticals, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核醫影像設備市場規模將達到 95.5 億美元，複合年成長率為 6.09%。

關鍵市場統計數據
基準年 2024 59.5億美元
預計年份：2025年 62.9億美元
預測年份 2032 95.5億美元
複合年成長率 (%) 6.09%

本文簡要概述了技術創新、商業壓力和不斷變化的臨床需求如何重塑核子醫學攝影造影設備的部署和應用。

核子醫學掃描術診斷領域正處於曲折點，技術創新、不斷變化的臨床需求和政策環境正在再形成診斷和治療路徑。檢測器材料、重建演算法和混合成像架構的進步提高了核醫學檢查的靈敏度和特異性，使臨床醫生能夠更早發現病變並更詳細地表徵疾病的生物學特徵。同時，放射性藥物生產和分銷網路的日益成熟，擴大了可用示蹤劑的種類，從而拓展了臨床適應症，並增加了對特定成像方式設備的需求。

儘管技術不斷進步，但相關人員在採購決策、營運流程和資本配置方面仍面臨日益複雜的挑戰。影像服務供應商必須權衡對尖端PET和SPECT平台的投資與人員配備、試劑供應和報銷框架等實際情況。因此，臨床、營運和商業領導者需要基於證據的訊息，將儀器性能與臨床影響和營運可行性聯繫起來。本執行摘要總結了這些動態，重點關注結構性變化、監管和貿易影響、細分市場洞察、區域性考慮以及實用建議，旨在幫助決策者清晰、自信地應對近期市場格局。

模式融合、放射性藥物多樣化和人工智慧主導的分析將如何重新定義臨床工作流程、商業模式和夥伴關係策略？

核子醫學影像領域正經歷著一場變革性的轉變，這場轉變由三個相互關聯的因素所驅動：影像方式的融合、放射性藥物的多樣化以及計算技術的增強。 PET/CT 和 SPECT/CT 一體化平台實現了解剖結構與功能之間的無縫關聯，從而提高了診斷的準確性和手術效率。同時，放射性藥物套件也在不斷擴展，納入了靶向特異性更高的示踪劑以及能夠將診斷與標靶治療相結合的診療一體化藥物組合，從而改變了影像中心和腫瘤診所的臨床路徑和資金需求。

硬體和示蹤劑的創新與人工智慧和定量分析的進步相輔相成，正在改變影像的重建、解讀以及將其整合到臨床決策中的方式。機器學習主導的降噪和病灶檢測提高了有效通量並減少了重複檢查，而標準化的定量指標則增強了對病患監測。監管機構正日益明確醫療設備器材軟體（SaaS）的核准路徑，促使供應商調整產品藍圖，轉向檢驗的演算法組件。此外，供應鏈的韌性和本地化生產正在改變採購行為，並促進設備製造商、放射性藥物製造商和服務機構之間的策略聯盟。總而言之，這些轉變正在創造一個格局：長期領先地位不僅取決於設備規格，還取決於臨床價值、工作流程整合和生態系統協作。

評估2025年關稅政策如何改變了核子醫學影像設備相關人員的供應鏈採購行為和策略採購

2025年關稅政策為核子成像生態系統帶來了新的成本和物流複​​雜性，並對設備採購、備件庫存和放射性藥物供應鏈產生了連鎖反應。進口影像處理組件和製造投入品關稅的提高迫使供應商重新評估其全球採購佈局，並加速了關於近岸組裝、供應商多元化以及重新談判長期供應商合約的討論。重要的是，這些變化也影響臨床醫療機構的資本規劃，許多機構現在在進行設備更換和擴大決策時，會將更長的前置作業時間和更高的到岸成本考慮在內。

除了硬體之外，關稅也影響了放射性藥物耗材和專用硬體模組的流通，促使一些供應商整合物流，並尋求簡化產品配置，以減少對受關稅影響零件的依賴。為此，買家採取了多種應對策略，包括擴大服務協議範圍以維持運作、為關鍵備件儲備特定庫存緩衝，以及更多地使用多年期採購協議以確保價格可預測性。政策主導的成本上漲也加速了對基於價值的採購模式的需求，在這種模式下，設備選擇標準更注重吞吐量、試劑效率和可維護性，而不是主要規格參數。雖然關稅造成了短期成本壓力，但也催化了結構性轉變，這些轉變有可能透過區域化供應鏈網路和策略供應商夥伴關係來提高長期供應韌性。

產品類型情報揭示了放射性藥物的臨床用途和最終用戶類型如何決定採購優先順序和營運權衡。

按細分市場解讀市場動態，可以揭示影響投資決策和實踐設計的、產品、示踪劑、臨床和終端用戶方面的洞察。在產品架構方面，平面閃爍顯像系統繼續滿足低複雜度診斷流程的需求，而正子斷層掃描 (PET) 掃描儀則提供靈敏的功能性影像，這對於高階腫瘤學和神經病學應用至關重要。單光子發射電腦斷層掃描 ( SPECT) 掃描儀則介於兩者之間，其中混合型 SPECT 影像系統透過 CT 配準擴展了診斷功能，而獨立式 SPECT 平台則為優先考慮吞吐量的機構提供了經濟高效的解決方案。這些產品差異影響著不同臨床環境下的採購邏輯。

放射性藥物的可用性和特性正產生類似的影響。氟代脫氧葡萄糖仍然是代謝成像的核心示蹤劑，而鎵-68在胜肽受體成像和新型診療一體化應用中的實用性，推動了臨床對現場或區域發生器解決方案的需求。碘-131在已確立的治療適應症中仍然具有重要意義，而Technetium-99m由於其良好的物理特性和廣泛的配銷通路，繼續支持各種常規閃爍掃描檢查。在臨床上，心臟病學和腫瘤學主導高階影像模式的使用，而神經病學和感染疾病診斷則需要專門的示蹤劑和通訊協定。整形外科依賴更平面的SPECT技術進行標靶評估。診斷影像中心優先考慮吞吐量和多重模式影像能力，以滿足轉診網路的需求；醫院和診所需要與更廣泛的電子健康記錄和介入手術室整合；而研究機構則需要能夠支援臨床實驗示蹤劑和快速通訊協定變更的靈活平台。選擇與示蹤劑策略、臨床適應症和最終用戶操作限制一致的產品，對於最佳化資本回報和臨床療效至關重要。

從區域視角分析美洲、歐洲、中東和非洲以及亞太地區的法律規範、報銷機制和生產佈局如何驅動不同的應用和夥伴關係選擇。

區域動態正在影響美洲、歐洲、中東和非洲以及亞太地區的應用曲線、監管複雜性和供應鏈選擇，每個地區都呈現出獨特的部署條件和戰略機會。在美洲，成熟的報銷框架和密集的轉診網路有利於先進PET平台和混合系統的快速普及，而活躍的臨床研究活動則推動了新型示踪劑和診療一體化工作流程的早期應用。另一方面，一些公共醫療機構的資金限制促使他們選擇資金籌措方案和管理服務協議，以降低前期支出，同時確保能夠獲得最新的影像處理技術。

歐洲、中東和非洲的監管和報銷環境各不相同。一些國家實行集中式的衛生技術評估流程和嚴格的價值驗證計劃，而新興市場則對經濟高效的SPECT和平面成像系統表現出需求。這種區域差異也為平台標準化創造了機遇，從而支持跨國臨床試驗和跨境服務模式。在亞太地區，診斷基礎設施的快速擴張、對本地放射性藥物生產的投資以及政府對國內生產的大力支持，正在加速PET和SPECT系統的應用。這些市場的特點是臨床需求量大，並且對包括遠端監測和人工智慧驅動的工作流程最佳化在內的整合服務模式有著強烈的需求。在每個區域內，軟體和放射性藥物核准方面的監管趨勢、不斷變化的報銷政策以及本地生產能力，將繼續推動差異化的應用模式和夥伴關係模式。

領先的供應商和服務供應商如何整合硬體、軟體和放射藥學夥伴關係關係，以創建穩健的經常性收入模式和競爭優勢

核子醫學影像生態系統中的主要企業正在圍繞整合硬體、放射性藥物和軟體主導的臨床工作流程的綜合價值主張調整其策略。供應商更加重視可維護性和正常運作時間提案，因為他們認知到設備生命週期經濟性和營運連續性對醫院和診斷中心至關重要。與物流製造商和物流供應商建立策略合作夥伴關係已成為確保端到端解決方案的關鍵策略，該解決方案將示踪劑的可用性與掃描儀的部署聯繫起來，從而縮短患者運作時間並簡化臨床排班。

同時，眾多公司正大力投資可擴展的軟體平台，以提供定量成像、決策支援和遠端監測服務。這些服務旨在創造穩定的收入來源，並支援與吞吐量、診斷準確性和治療方案有效性掛鉤的績效合約。為了吸引資源有限的買家，各公司也嘗試靈活的商業模式，例如按掃描付費合約和基於訂閱的高級分析服務。最後，成功的公司優先考慮監管策略和臨床證據的生成，並與學術中心合作，檢驗新的示踪劑、重建演算法和診療一體化路徑，從而在競爭激烈的採購過程中凸顯其差異化提案主張。

為供應商、製造商和投資者提供可操作的策略重點，以增強供應鏈韌性、加速軟體應用，並將資本部署與臨床價值掛鉤。

產業領導者應優先採取策略行動，以平衡短期韌性與基於價值的個人化醫療的長期定位。首先，應實現採購管道多元化並加強與供應商的關係，以減輕關稅造成的供應中斷。對於關鍵零件，應選擇性地進行近岸外包，同時保持專用零件和耗材的多來源選擇。其次，應加快軟體和分析技術的投資，以提高掃描器的使用率和診斷效率。檢驗的人工智慧工具和定量報告系統可以顯著降低營運成本並提高臨床療效，從而為差異化採購提供有力支援。

第三，我們將與物流生產商和物流供應商建立策略夥伴關係，使示蹤劑的供應與臨床計劃相匹配，並實現一體化服務交付。第四，我們將採用靈活的商業模式，降低購買者的資金門檻，例如管理服務協議、基於績效的定價以及延長設備生命週期的模組化升級方案。第五，我們將透過實證實踐和衛生經濟學示範計劃，積極與監管機構和支付方溝通，以確保獲得有利的報銷，並簡化軟體功能的核准流程。這些措施將共同支持永續成長，並改善不同醫療機構獲得先進診斷和治療工作流程的機會。

採用嚴謹的混合方法研究途徑，結合專家訪談、工具性分析、監管研究和供應鏈圖譜分析，以檢驗策略見解和假設。

本執行報告的研究採用多學科方法，結合一手和二手研究，建構了可靠的依證。一手研究包括對臨床終端使用者、採購負責人和服務工程師進行結構化訪談，以了解營運限制、培訓需求和運作優先事項。這些定性見解與設備規格、臨床試驗結果和監管核准趨勢的技術分析相結合，以評估不同平台類型的能力差異。供應鏈圖譜確定了組件和示蹤劑分銷的關鍵節點，情境分析則探討了政策變化和關稅相關成本波動的影響。

二次研究利用同行評審的臨床文獻、監管文件、專利資料庫以及來自製造商和醫療保健機構的公開資訊，檢驗有關技術性能和臨床效用的提案。在適用情況下，根據臨床指引更新和已發表的比較效果研究評估了示蹤劑的具體價值主張。透過反覆的同儕檢驗以及記錄資料來源和研究假設，確保了調查方法的嚴謹性。這使得我們能夠從整體觀點進行策略決策，而無需依賴專有或專有的預測結果。

對整合臨床路徑供應​​彈性及檢驗的軟體產品如何決定核子醫學攝影成像市場長期領導地位進行全面分析

摘要：核醫影像市場正從以設備為中心的市場轉向一體化的臨床生態系統轉變，其長期成功取決於放射性藥物的供應、軟體智慧和供應鏈韌性。混合成像和演算法重構的技術進步拓展了診斷能力，同時也提高了營運整合和臨床檢驗的難度。關稅主導的複雜性給採購和物流帶來了新的短期壓力，但也促使企業進行策略調整，從長遠來看，這可能會形成更具韌性的供應架構和更本地化的能力。

因此，決策者應根據臨床應用案例、營運限制和當地監管實際情況做出投資選擇。透過優先選擇兼具診斷準確性、工作流程效率和服務穩定性的解決方案，醫療機構可以在降低整體擁有成本的同時改善患者預後。隨著治療路徑越來越依賴精準的分子影像和診療一體化，專注於整合產品、靈活的商業性模式和檢驗的軟體組件的製造商和投資者將佔據有利地位，從而獲得持久價值。未來的道路需要協作的生態系統、主導的產品設計以及能夠將技術前景轉化為可衡量的臨床影響的實用商業模式。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工智慧增強影像重建技術在數位SPECT/CT系統中的應用日益廣泛
  • 增加針對個人化癌症治療的診療整合放射性核種研發的投資
  • 將小型迴旋加速器模組整合到核子成像實驗室中，以緩解同位素供應限制。
  • 全球主要市場放射性藥物核准途徑的監管協調
  • 開發用於偏遠地區和緊急情況下現場核子醫學掃描術診斷的可攜式伽馬攝影機
  • α粒子成像劑的出現及其在腫瘤高解析度分子特性中的應用
  • 影像設備製造商與放射性藥物製造商合作，以提高物流效率
  • 擴展混合型PET/MRI掃描儀，以實現同時進行代謝和軟組織成像
  • 為每位患者實施先進的劑量測定軟體，以實現精確的輻射劑量管理。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 核子醫學影像設備市場（依產品分類）

  • 平面閃爍成像系統
  • 正子斷層掃描（PET）掃描儀
  • 單光子發射電腦斷層掃描（SPECT）掃描儀
    • 混合式SPECT影像系統
    • 獨立式SPECT影像系統

9. 核子醫學影像設備市場 - 放射性藥物

  • 氟代脫氧葡萄糖（FDG）
  • 鎵-68
  • 碘-131
  • Technetium-99m

第10章 核子醫學影像設備市場（依應用領域分類）

  • 心臟病學
  • 感染疾病的診斷
  • 神經病學
  • 腫瘤學
  • 整形外科

第11章 核子醫學影像設備市場（依最終用戶分類）

  • 診斷影像中心
  • 醫院和診所
  • 研究所

第12章 核醫影像設備市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 核醫影像設備市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國核子醫學影像設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Absolute Imaging Inc.
    • Advanced Accelerator Applications SA by Norvatis
    • Agfa-Gevaert NV
    • Bayer AG
    • Bozlu Holding AS
    • Bracco Imaging SpA
    • Canon Medical Systems Corporation
    • CMR Naviscan Corporation
    • Cubresa Inc.
    • DDD-Diagnostic A/S
    • Digirad Corporation
    • Edge Medical Solutions Private Limited
    • GE HealthCare Technologies Inc.
    • Koninklijke Philips NV
    • Mediso Ltd.
    • MR Solutions Ltd.
    • Neusoft Medical Systems Co., Ltd.
    • PerkinElmer Inc.
    • Revvity Inc
    • Rigaku Corporation
    • Shimadzu Corporation
    • Siemens AG
    • Surgiceye GmbH
    • United Imaging Healthcare Co., Ltd.
Product Code: MRR-50124643717F

The Nuclear Imaging Equipment Market is projected to grow by USD 9.55 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.95 billion
Estimated Year [2025] USD 6.29 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 6.09%

A concise framing of how technological innovation operational pressures and evolving clinical needs are reshaping nuclear imaging equipment deployment and adoption

The field of nuclear imaging equipment stands at an inflection point where technological innovation, evolving clinical needs, and shifting policy environments converge to reshape diagnostic and therapeutic pathways. Advances in detector materials, reconstruction algorithms, and hybrid imaging architectures have elevated both the sensitivity and specificity of nuclear scans, enabling clinicians to detect pathology earlier and to characterize disease biology with greater granularity. At the same time, the maturation of radiopharmaceutical manufacturing and distribution networks has expanded the portfolio of available tracers, which in turn broadens clinical indications and drives demand for modality-specific instrumentation.

Despite these technical gains, stakeholders face increasing complexity in procurement decisions, operational workflows, and capital allocation. Imaging service providers must balance investments in cutting-edge PET and SPECT platforms against the realities of staffing, reagent availability, and reimbursement frameworks. Consequentially, leaders across clinical, operational, and commercial functions require evidence-based intelligence that links device capability to clinical impact and operational feasibility. This executive summary synthesizes those dynamics, highlighting structural shifts, regulatory and trade influences, segmentation-level insights, regional considerations, and practical recommendations that equip decision-makers to navigate the near-term landscape with clarity and confidence.

How modality convergence radiopharmaceutical diversification and AI-driven analytics are collectively redefining clinical workflows commercial models and partnership strategies

The nuclear imaging landscape is undergoing transformative shifts driven by three interrelated vectors: modality convergence, radiopharmaceutical diversification, and computational augmentation. Hybridization of imaging systems has moved beyond single-point upgrades to become a dominant architectural principle, with integrated PET/CT and SPECT/CT platforms enabling seamless anatomical-functional correlation that improves diagnostic confidence and procedural efficiency. Concurrently, the radiopharmaceutical toolkit has expanded to incorporate tracers with higher target specificity and theranostic pairings that link diagnosis to targeted therapy, thereby altering clinical pathways and capital requirements for imaging centers and oncology clinics.

Complementing hardware and tracer innovation, advances in artificial intelligence and quantitative analytics are changing how images are reconstructed, interpreted, and integrated into clinical decision-making. Machine learning-driven denoising and lesion detection improve effective throughput and reduce repeat scans, while standardized quantitative metrics enhance longitudinal patient monitoring. Regulatory agencies are increasingly defining pathways for software-as-a-medical-device approvals, prompting vendors to reorient product roadmaps toward validated algorithmic components. Moreover, supply chain resiliency and localized manufacturing initiatives are shifting procurement behavior, encouraging strategic partnerships between equipment manufacturers, radiopharmaceutical producers, and service organizations. Taken together, these shifts create a landscape in which clinical value, workflow integration, and ecosystem partnerships determine long-term leadership rather than device specifications alone.

Assessment of how tariff policy enacted in 2025 has altered supply chains procurement behavior and strategic sourcing among nuclear imaging equipment stakeholders

Tariff policy implemented in 2025 introduced a new layer of cost and logistical complexity for the nuclear imaging ecosystem, with ramifications reverberating across device procurement, spare-parts inventory, and radiopharmaceutical supply chains. Increased duties on imported imaging components and manufacturing inputs have pressured vendors to reassess global sourcing footprints, accelerating conversations about nearshoring assembly, diversifying supplier bases, and renegotiating long-term supplier agreements. Importantly, this dynamic has also influenced capital planning horizons for clinical providers, many of whom are now factoring extended lead times and higher landed costs into replacement and expansion decisions.

Beyond hardware, tariffs have affected the movement of radiopharmaceutical-related consumables and specialized hardware modules, prompting some suppliers to consolidate logistics and to pursue simplified product configurations that reduce dependency on tariffed components. In response, purchasers have adopted a mix of mitigation strategies including expanded service contracts to preserve uptime, selective inventory buffers for critical spare parts, and greater use of multi-year procurement agreements to lock in pricing predictability. Policy-driven cost inflation has also accelerated demand for value-based procurement models, wherein equipment selection criteria emphasize throughput, reagent efficiency, and serviceability over headline specifications. While tariffs introduce short-term cost pressures, they have also catalyzed structural shifts that may improve long-term supply resilience through localized supply networks and strategic vendor partnerships.

Segment-aware intelligence revealing how product categories radiopharmaceutical classes clinical applications and end-user types jointly determine procurement priorities and operational trade-offs

Segment-focused interpretation of market dynamics reveals distinct product, tracer, clinical, and end-user realities that influence investment decisions and operational design. Within product architecture, planar scintigraphy imaging systems continue to serve lower-complexity diagnostic workflows, while positron emission tomography scanners deliver high-sensitivity functional imaging essential for advanced oncology and neurology applications. Single Photon Emission Computed Tomography scanners occupy a middle ground where hybrid SPECT imaging systems extend diagnostic capability through CT co-registration and stand-alone SPECT platforms offer cost-effective solutions for centers prioritizing throughput. These product distinctions drive procurement logic across diverse clinical settings.

Radiopharmaceutical availability and characteristics exert a parallel influence. Fluorodeoxyglucose remains a central workhorse tracer for metabolic imaging, whereas Gallium-68's utility in peptide receptor imaging and novel theranostic applications has increased clinical demand for on-site or regional generator solutions. Iodine-131 retains relevance for established therapeutic indications, and Technetium-99m continues to underpin a broad array of routine scintigraphic studies due to its favorable physical properties and wide distribution infrastructure. Clinically, cardiology and oncology dominate utilization patterns for high-end modalities, with neurology and infectious disease diagnosis requiring specialized tracers and protocols. Orthopedics relies more on planar and SPECT techniques for targeted evaluations. End-user distinctions matter: diagnostic imaging centers prioritize throughput and multi-modality capability to serve referral networks, hospitals and clinics require integration with broader electronic medical records and interventional suites, and research institutes demand flexible platforms that support investigational tracers and rapid protocol changes. Aligning product selection with tracer strategy, clinical indication, and end-user operational constraints is essential to optimize returns on capital and clinical impact.

A regional lens on how regulatory frameworks reimbursement dynamics and manufacturing footprints across Americas EMEA and Asia-Pacific drive differentiated adoption and partnership choices

Regional dynamics shape adoption curves, regulatory complexity, and supply-chain choices across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each geography presenting unique deployment conditions and strategic opportunities. In the Americas, mature reimbursement frameworks and high-density referral networks favor rapid uptake of advanced PET platforms and hybrid systems, while strong clinical research activity drives early adoption of novel tracers and theranostic workflows. Conversely, capital constraints at some public facilities encourage financing options and managed service agreements that reduce upfront expenditure while preserving access to modern imaging capability.

Europe, Middle East & Africa present a heterogeneous set of regulatory and reimbursement environments where centralized health technology assessment processes in some jurisdictions drive rigorous value demonstration, and in others, emerging markets exhibit demand for cost-efficient SPECT and planar systems. The region's diversity also creates opportunities for platform standardization that supports multinational clinical trials and cross-border service models. In the Asia-Pacific region, rapid expansion of diagnostic infrastructure, investments in local radiopharmaceutical production, and strong government interest in domestic manufacturing have accelerated deployment of both PET and SPECT systems. These markets are characterized by a combination of high-volume clinical demand and an appetite for integrated service models, including remote monitoring and AI-enabled workflow optimization. Across regions, regulatory pathways for software and radiopharmaceutical approval, reimbursement policy shifts, and local manufacturing capabilities will continue to drive differentiated adoption patterns and partnership models.

How major vendors and service providers are integrating hardware software and radiopharmaceutical partnerships to create resilient recurring-revenue models and competitive differentiation

Leading organizations in the nuclear imaging equipment ecosystem are realigning strategies around integrated value propositions that combine hardware, radiopharmaceutical enablement, and software-driven clinical workflows. Vendors are placing greater emphasis on serviceability and uptime guarantees, recognizing that equipment lifecycle economics and operational continuity are decisive factors for hospitals and diagnostic centers. Strategic alliances with radiopharmaceutical manufacturers and logistics providers have become frontline tactics to secure end-to-end solutions that link tracer availability with scanner deployment, thereby reducing patient wait times and simplifying clinical scheduling.

In parallel, a cohort of companies is investing heavily in scalable software platforms to deliver quantitative imaging, decision support, and remote monitoring services. These offerings are designed to create sticky revenue streams and to enable performance-based contracts tied to throughput, diagnostic accuracy, or treatment planning efficacy. Companies are also experimenting with flexible commercial models including pay-per-scan arrangements and subscription-based access to premium analytics, which appeal to resource-constrained buyers. Finally, successful players prioritize regulatory strategy and clinical evidence generation, partnering with academic centers to validate new tracers, reconstruction algorithms, and theranostic pathways that support differentiated value propositions in competitive procurement processes.

Actionable strategic priorities for providers manufacturers and investors to enhance supply resilience accelerate software adoption and link capital deployment to clinical value

Industry leaders should prioritize a triage of strategic actions that balance near-term resilience with long-term positioning for value-based, personalized care. First, diversify sourcing and strengthen supplier relationships to mitigate tariff-induced supply disruptions; engage in selective nearshoring for critical components while maintaining multi-sourced options for specialized parts and consumables. Second, accelerate investments in software and analytics that improve scanner utilization and diagnostic throughput; validated AI tools and quantitative reporting systems can materially reduce operational costs and improve clinical impact, thereby supporting differentiated procurement justifications.

Third, cultivate strategic partnerships with radiopharmaceutical manufacturers and logistics providers to ensure tracer availability aligns with clinical schedules and to enable integrated service offerings. Fourth, adopt flexible commercial models that reduce capital barriers for buyers, such as managed service contracts, outcome-linked pricing, and modular upgrade paths that extend device lifecycles. Fifth, engage proactively with regulators and payers through robust evidence generation and health economic demonstration projects to secure favorable reimbursement and to streamline approvals for software-enabled features. Collectively, these actions will support sustainable growth while improving access to advanced diagnostic and theranostic workflows for diverse care settings.

A rigorous mixed-methods research approach combining expert interviews device analytics regulatory review and supply-chain mapping to validate strategic insights and assumptions

The research underpinning this executive synthesis combined a multidisciplinary approach incorporating primary and secondary inputs to create a robust evidence base. Primary research included structured interviews with clinical end-users, procurement leaders, and service engineers to capture operational constraints, training needs, and uptime priorities. These qualitative insights were triangulated with technical analyses of device specifications, clinical trial outcomes, and regulatory approval trends to assess capability differentials among platform types. Supply chain mapping identified critical nodes for components and tracer distribution, while scenario analysis explored sensitivity to policy shifts and tariff-related cost movements.

Secondary research drew on peer-reviewed clinical literature, regulatory filings, patent databases, and public disclosures from manufacturers and healthcare providers to validate assertions regarding technology performance and clinical utility. Where applicable, clinical guideline updates and published comparative effectiveness studies informed assessments of tracer-specific value propositions. Throughout the research process, methodological rigor was maintained through iterative validation with subject-matter experts and by documenting data provenance and analytical assumptions. The outcome is a synthesized perspective designed to inform strategic decision-making without relying on proprietary or proprietary forecasting outputs.

Synthesis of how integrated clinical pathways supply resilience and validated software offerings will determine long-term leadership in nuclear imaging equipment markets

In summary, the nuclear imaging equipment landscape is evolving from a device-centric market into an integrated clinical ecosystem where radiopharmaceutical availability, software intelligence, and supply-chain resilience determine long-term success. Technological advances in hybrid imaging and algorithmic reconstruction have expanded diagnostic capability while also raising the bar for operational integration and clinical validation. Tariff-driven complexities introduced new short-term pressures on procurement and logistics, but they also incentivized strategic adjustments that may yield more resilient supply architectures and localized capability over time.

Decision-makers should therefore align investment choices with clinical use cases, operational constraints, and regional regulatory realities. By privileging solutions that combine diagnostic accuracy, workflow efficiency, and service robustness, providers can deliver improved patient outcomes while containing total cost of ownership. Manufacturers and investors that focus on integrated offerings, flexible commercial arrangements, and validated software components will be positioned to capture enduring value as care pathways increasingly depend on precise molecular imaging and theranostic alignment. The path forward requires collaborative ecosystems, evidence-driven product design, and pragmatic commercial models that translate technological promise into measurable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of digital SPECT/CT systems with AI-enhanced image reconstruction
  • 5.2. Rising investment in theranostic radionuclide development for personalized cancer treatment
  • 5.3. Integration of compact cyclotron modules within nuclear imaging labs to reduce isotope supply constraints
  • 5.4. Regulatory harmonization of radiopharmaceutical approval pathways across key global markets
  • 5.5. Development of portable gamma cameras for point-of-care nuclear imaging in remote and emergency settings
  • 5.6. Emergence of alpha-particle imaging agents for high-resolution molecular characterization of tumors
  • 5.7. Collaboration between imaging equipment manufacturers and radiopharmacies for streamlined logistics
  • 5.8. Expansion of hybrid PET/MRI scanners to leverage simultaneous metabolic and soft tissue imaging
  • 5.9. Implementation of advanced dosimetry software for precise patient-specific radiation dose management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Imaging Equipment Market, by Product

  • 8.1. Planar Scintigraphy Imaging Systems
  • 8.2. Positron Emission Tomography (PET) Scanners
  • 8.3. Single Photon Emission Computed Tomography (SPECT) Scanners
    • 8.3.1. Hybrid SPECT Imaging Systems
    • 8.3.2. Standalone SPECT Imaging Systems

9. Nuclear Imaging Equipment Market, by Radiopharmaceuticals

  • 9.1. Fluorodeoxyglucose (FDG)
  • 9.2. Gallium-68
  • 9.3. Iodine-131
  • 9.4. Technetium-99m

10. Nuclear Imaging Equipment Market, by Application

  • 10.1. Cardiology
  • 10.2. Infectious Disease Diagnosis
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Nuclear Imaging Equipment Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Nuclear Imaging Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Imaging Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Imaging Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Absolute Imaging Inc.
    • 15.3.2. Advanced Accelerator Applications S.A. by Norvatis
    • 15.3.3. Agfa-Gevaert N.V
    • 15.3.4. Bayer AG
    • 15.3.5. Bozlu Holding A. S.
    • 15.3.6. Bracco Imaging S.p.A.
    • 15.3.7. Canon Medical Systems Corporation
    • 15.3.8. CMR Naviscan Corporation
    • 15.3.9. Cubresa Inc.
    • 15.3.10. DDD-Diagnostic A/S
    • 15.3.11. Digirad Corporation
    • 15.3.12. Edge Medical Solutions Private Limited
    • 15.3.13. GE HealthCare Technologies Inc.
    • 15.3.14. Koninklijke Philips N.V.
    • 15.3.15. Mediso Ltd.
    • 15.3.16. MR Solutions Ltd.
    • 15.3.17. Neusoft Medical Systems Co., Ltd.
    • 15.3.18. PerkinElmer Inc.
    • 15.3.19. Revvity Inc
    • 15.3.20. Rigaku Corporation
    • 15.3.21. Shimadzu Corporation
    • 15.3.22. Siemens AG
    • 15.3.23. Surgiceye GmbH
    • 15.3.24. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NUCLEAR IMAGING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NUCLEAR IMAGING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEAR IMAGING EQUIPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 232. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 236. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 237. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 240. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 265. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 271. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 272. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 273. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 277. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 280. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 281. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 283. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 284. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 285. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 288. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)